Guided Therapeutics (GTHP) Total Non-Current Liabilities (2013 - 2026)
Guided Therapeutics (GTHP) posted Total Non-Current Liabilities of $694000.0 for Q4 2025, up 778.48% sequentially from $79000.0 in Q3 2025, and up 519.64% YoY from $112000.0 in Q4 2024.
Guided Therapeutics (GTHP) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Guided Therapeutics has reported Total Non-Current Liabilities for 13 years, with the latest figure at $694000.0 in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 519.64% year-over-year to $694000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $694000.0 (up 519.64% YoY) and the FY2025 annual result came in at $694000.0, up 519.64% from the prior year.
- Total Non-Current Liabilities advanced to $694000.0 in Q4 2025 per GTHP's latest filing, from $79000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.8 million in Q4 2021 and troughed at $35000.0 in Q2 2025.
- A 5-year average of $870950.0 and a median of $710500.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities plunged 90.6% in 2024, then surged 519.64% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $1.8 million in 2021, then slipped by 22.95% to $1.4 million in 2022, then tumbled by 51.74% to $666000.0 in 2023, then sank by 83.18% to $112000.0 in 2024, then soared by 519.64% to $694000.0 in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $694000.0, $79000.0, and $35000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 21.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 40.90 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 42.74 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 2.57 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 3.68 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 23.89 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 9.07 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 3.44 Bn |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | 789,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 789,000.00 |
| Dec 31, 2025 | 694,000.00 |
| Sep 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 96,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Sep 30, 2024 | 142,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Dec 31, 2023 | 666,000.00 |
| Sep 30, 2023 | 693,000.00 |
| Jun 30, 2023 | 727,000.00 |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.27 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 1.79 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 1.72 Mn |